News & Media

Valeant agreed to buy AB Sanitas for about 314 million euros ($442 million) to add dermatology drugs in eastern and central Europe

The Province of Manitoba and Manitoba Hydro are entering an agreement with Nissan Canada to work together on initiatives that will help advance the use of plug-in electric vehicles in the province, Innovation, Energy and Mines Minister Dave Chomiak announ

The Food Development Centre (FDC) is working with the Manitoba Agri-Health Research Network to make food a part of a treatment process to improve quality of life. Along with two other organizations working with the support of MAHRN (the Canadian Centre fo

The Sanford Project & DiaMedica announced the successful completion of a study involving DM-199 in preventing the onset of Type 1 diabetes in the non-obese diabetic mouse model

The Richardson Centre for Functional Foods and Nutraceuticals is five years old and to mark the occasion it was joined by the Honourable Erin Selby, Minister of Advanced Education and Literacy, as it signed two international research agreements

Premier Greg Selinger announced a new Science Education Action Plan that includes $25 million over five years for science classroom renewal, teacher training and new strategic partnerships to promote Manitoba's science programming

GVI Clinical Development Solutions Inc. and Guangzhou, China based Guangzhou IRD Medicine Company, announce the signing of a Memorandum of Understanding to create a joint venture company called IRD-CDS, based in China

Regulations for foods and natural health products, and what you can say about them, vary from country to country.

Premier Greg Selinger today announced the province is committing to invest $70 million in a new-state-of-the-art facility for CancerCare Manitoba to improve diagnostics, treatment and research that will help Manitoba families affected by this disease.

Valeant filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc. for removal of Cephalon's current Board of Directors and election of its seven nominees in their

DiaMedica announced the company's entry into an evaluation agreement with the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health

IMRISNV will provide important new capabilities for clinicians at University of Utah Hospital's leading edge stroke center

Kane Biotech announced a non-brokered private placement offering for gross proceeds of up to $1,500,000 from the sale of up to 12,500,000 units at a price of $0.12 per unit

Valeant Pharmaceuticals International, Inc. announced that it had made a proposal to the Board of Directors of Cephalon, Inc. to acquire Cephalon for $73.00 per share in cash

The Governments of Canada and Manitoba are investing $400,000 to help survey Manitobans about their opinions, preferences and experiences with food and health which will lead to food development and creating a healthier future for Manitobans

A two-year-long clinical study on the health benefits of flax seeds is complete and, depending on the results, it could yield a rich supply of potential products for commercialization

Valeant Pharmaceuticals International ranks first among companies in the Healthcare sector as measured by relative performance

The Governments of Canada and Manitoba announced they are contributing to a $10 million strategic initiative to enhance the capacity of the province’s medical device industry to develop and commercialize specialized joint replacement technology

The Governments of Canada and Manitoba are committing $406,000 in funding in 2010/11 to the Manitoba Agri-Health Research Network Inc. (MAHRN) to support the further research, development and commercialization of projects that identify links between food

Cangene returned to profitability in the second quarter with revenue up compared to the year before

AstraZeneca PLC and Bristol-Myers Squibb Co. say their diabetes drug Onglyza has been approved in Europe for treating people with Type 2 diabetes who have moderate or severe renal impairment